

January 21, 2025

DCS-CRD BSE Limited First Floor, New Trade Wing Rotunda Building, Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai 400001 Fax No.2272 3121/2037/2039 Stock Code: 543213	Listing Compliance National Stock Exchange of India Ltd. Exchange Plaza, 5 th Floor Plot No. C/1, 'G' Block, Bandra- Kurla Complex Bandra East Mumbai 400051 Fax No.2659 8237/8238 Stock Code: ROSSARI
---	--

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on January 21, 2025.

Ref: Regulation 30 of Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations").

With regard to the captioned matter and in compliance with the Listing Regulations, this is to inform you that at the meeting of the Board of Directors of the Company, which commenced at 05:30 P.M. and concluded at 06:45 P.M. today i.e. January 21, 2025, the Board of Directors have, inter alia, approved the following:

1. Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2024

Copy of Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2024 of the Financial Year 2024-25 are enclosed herewith.

The aforesaid results were reviewed by the Audit Committee and subsequently, approved and taken on record by the Board of Directors of the Company. We would further like to inform that the Statutory Auditors of the Company have subjected the aforesaid results to "Limited Review" and the same is enclosed herewith.

2. Shifting of Registered Office of the Company, within local limits of Mumbai city

The Board of Directors of the Company approved shifting of the registered office of the Company within the local limits of Mumbai city from 201 A - B, 2nd Floor, Akruti Corporate Park, L.B.S Marg, Next to GE Gardens, Kanjurmarg (W), Mumbai - 400078 to **Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai Maharashtra, India, 400079** effective from February 01, 2025.

ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company), CIN: L24100MH2009PLC194818

Regd. Office : 201 A - B, 2nd Floor, Akruti Corporate Park, L.B.S Marg, Next to GE Gardens, Kanjurmarg (W), Mumbai - 400078, India. **T** : +91-22-6123 3800 **F** : +91-22-2579 6982

Factory : Plot No. 10 & 11, Survey No. 90/1/10/ & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. **T** : 0260-669 3000

: Plot No. D3/24/3, Opposite Yokohama Tyre, Phase III, G.I.D.C Dahej, Village Galenda, Taluka Vagra, Bharuch-Gujarat - 392130, India. **T** : +91 2641-661621

 info@rossari.com

 www.rossari.com

3. Allotment of Equity Shares under the Rossari Employee Option Plan – 2019

With reference to the in-principle approval received from BSE Limited Letter Ref. No. DCS/FL/MJ/ESOP-IP/1257/2021-22 dated May 25, 2021 and National Stock Exchange of India Limited Letter Ref. No. NSE/LIST/26888 dated May 28, 2021 for issue and allotment of 1500000 Equity Shares of Rs. 2/- each to be issued under Rossari Employee Stock Option Plan - 2019 (“ESOP 2019”), the Board of Directors of the Company approved the allotment of 7500 Equity Shares of Rs. 2/- each fully paid to the grantees on exercise of the options granted to them pursuant to ESOP 2019.

The said Equity shares shall rank pari passu, in all respects with the existing equity shares of the Company. Consequent, to the allotment of the aforesaid equity shares, the issued and the paid-up equity share capital of the Company stands increased to Rs. 11,07,27,532 consisting of 55363766 Equity Shares of Rs. 2/- each.

The details as required under the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 are enclosed as **Annexure – I**.

4. Appointment of M/s. Shah Patel & Associates, Practicing Company Secretaries, as Secretarial Auditor

The Board of Directors of the Company approved appointment of M/s. Shah Patel & Associates, Practicing Company Secretaries, Mumbai, as Secretarial Auditor of the Company to conduct the Secretarial Audit for the Financial Year 2024-25.

The details as required under Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are enclosed as **Annexure-II**.

The same may please be taken on record and suitably disseminated to all concerned.

Thanking you,

Yours Sincerely,
For Rossari Biotech Limited

**Parul
Gupta** Digitally signed
by Parul Gupta
Date: 2025.01.21
18:48:30 +05'30'



Parul Gupta
Head - Company Secretary & Legal
Membership No.: A38895

Encl.: as above

ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company), CIN: L24100MH2009PLC194818

Regd. Office : 201 A - B, 2nd Floor, Akruti Corporate Park, L.B.S Marg, Next to GE Gardens, Kanjurmarg (W), Mumbai - 400078, India. **T** : +91-22-6123 3800 **F** : +91-22-2579 6982

Factory : Plot No. 10 & 11, Survey No. 90/1/10/ & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. **T** : 0260-669 3000

: Plot No. D3/24/3, Opposite Yokohama Tyre, Phase III, G.I.D.C Dahej, Village Galenda, Taluka Vagra, Bharuch-Gujarat - 392130, India. **T** : +91 2641-661621

info@rossari.com

www.rossari.com

Annexure-I
Disclosure pursuant to Regulation 10(c) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021

Sr. No.	Particular	Disclosure – Rossari Employee Stock Option Plan – 2019
1.	Company name and address of Registered Office	Rossari Biotech Limited CIN: L24100MH2009PLC194818 Registered Office: 201 A - B, 2 nd Floor, Akruti Corporate Park, L.B.S Marg, Next to GE Gardens, Kanjurmarg (W), Mumbai 400078
2.	Name of the Stock Exchanges on which the Company's shares are listed	1. BSE Limited (BSE) 2. National Stock Exchange of India Limited (NSE)
3.	Filing date of the statement referred in regulation 10(b) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 with Stock Exchange	Filing date of statement is as follows: 1. BSE Limited: May 20, 2021 2. National Stock Exchange of India Limited: May 25, 2021
4.	Filing No., if any	BSE: 129899 NSE: 26888
5.	Title of the Scheme pursuant to which shares are issued, if any	Rossari Employee Stock Option Plan - 2019
6.	Kind of security to be listed	Equity Shares
7.	Par Value of the shares	Rs. 2/-
8.	Date of Issue of shares	January 21, 2025
9.	Number of shares issued	7500 Shares
10.	Certificate No., if applicable	Not applicable
11.	Distinctive Number of the shares, if applicable	55356267 to 55363766
12.	ISIN of the shares if issued in Demat	INE02A801020
13.	Exercise price per share	Rs. 425/-
14.	Premium per share	Rs. 423/-
15.	Total Issued shares after this issue	55363766 Shares
16.	Total Issued share capital after this issue	Rs. 11,07,27,532
17.	Details of any lock-in on the shares	Not applicable
18.	Date of expiry of lock-in	Not applicable
19.	Whether shares identical in all respects to existing shares, if not, when will they become identical	All equity shares allotted pursuant to exercise of stock options shall rank pari-passu with the existing equity shares of the Company
20.	Details of listing fees, if applicable	Not applicable


ROSSARI BIOTECH LIMITED


(An ISO 9001:2015 & 14001:2015 Certified Company), CIN: L24100MH2009PLC194818

Regd. Office : 201 A - B, 2nd Floor, Akruti Corporate Park, L.B.S Marg, Next to GE Gardens, Kanjurmarg (W), Mumbai - 400078, India. **T** : +91-22-6123 3800 **F** : +91-22-2579 6982

Factory : Plot No. 10 & 11, Survey No. 90/1/10/ & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. **T** : 0260-669 3000

: Plot No. D3/24/3, Opposite Yokohama Tyre, Phase III, G.I.D.C Dahej, Village Galenda, Taluka Vagra, Bharuch-Gujarat - 392130, India. **T** : +91 2641-661621

 info@rossari.com

 www.rossari.com

Annexure-II

Disclosure of information pursuant to Regulation 30 of Listing Regulations read with SEBI circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Sr. No.	Particulars	Disclosure
1.	Reason for change	Appointment of M/s. Shah Patel & Associates, Practicing Company Secretaries, Mumbai, as Secretarial Auditor of the Company to conduct the Secretarial Audit for the Financial Year 2024-25
2.	Date of appointment and Term of appointment	Appointed in the Board Meeting held on January 21, 2025 to conduct the Secretarial Audit for the Financial Year 2024-25. Term of appointment: 1 (one) year
3.	Brief Profile	M/s. Shah Patel & Associates is a Practicing Company Secretary firm registered with the Institute of Company Secretaries of India (ICSI) and bearing Peer Review Certificate Number: 1062/2021. M/s. Shah Patel & Associates has immense experience and specialize in dealing with matters relating to rendering professional services in area of Corporate Laws, Secretarial matters, Securities Laws, Corporate Governance matters, Corporate Restructuring, Mergers and Amalgamation, Legal Due Diligence, Corporate Disputes and NCLT Matters, SME Listing and all types of Company Law related compliances.

ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company), CIN: L24100MH2009PLC194818

Regd. Office : 201 A - B, 2nd Floor, Akruti Corporate Park, L.B.S Marg, Next to GE Gardens, Kanjurmarg (W), Mumbai - 400078, India. **T** : +91-22-6123 3800 **F** : +91-22-2579 6982

Factory : Plot No. 10 & 11, Survey No. 90/1/10/ & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. **T** : 0260-669 3000

: Plot No. D3/24/3, Opposite Yokohama Tyre, Phase III, G.I.D.C Dahej, Village Galenda, Taluka Vagra, Bharuch-Gujarat - 392130, India. **T** : +91 2641-661621

 info@rossari.com

 www.rossari.com

Walker Chandiook & Co LLP

16th Floor, Tower III,
One International Center,
S B Marg, Prabhadevi (W),
Mumbai - 400013
Maharashtra, India
T +91 22 6626 2600

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Rossari Biotech Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of **Rossari Biotech Limited** ('the Company') for the quarter ended **31 December 2024** and the year to date results for the period 01 April 2024 to 31 December 2024, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Rossari Biotech Limited

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiook & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013

Bharat Shetty

Partner

Membership No. 106815



UDIN: 25106815BMJIDY6212

Place: Mumbai

Date: 21 January 2025

ROSSARI BIOTECH LIMITED

(AN ISO9001:2005 & 14001:2015 Certified Company)



Regd. Office : 201 A & B, 2nd Floor, Akruti Corporate Park, L.B.S. Marg, Next to GE Gardens, Kanjurmarg (W) Mumbai – 400078
T +91-22-6123 3800 F +91-22- 25796982 E info@rossari.com W www.rossari.com CIN: L24100MH2009PLC194818

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2024

Rs. In million

Particulars	Quarter ended			Nine months ended		Year Ended
	31st December, 2024	30th September, 2024	31st December, 2023	31st December, 2024	31st December, 2023	31st March, 2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I INCOME						
Revenue from operations	3,682.78	3,359.89	2,987.52	10,049.75	8,891.06	12,029.10
Other Income	10.06	10.81	21.29	33.46	54.29	67.71
Total Income	3,692.84	3,370.70	3,008.81	10,083.21	8,945.35	12,096.81
II EXPENSES						
Cost of materials consumed	2,098.05	2,126.60	1,509.25	5,524.45	4,582.04	6,257.33
Purchase of stock-in-trade	577.39	494.04	543.00	1,911.79	2,150.96	2,849.89
Changes in inventory of finished goods, work-in-progress and stock-in-trade	(13.08)	(155.11)	110.93	(123.65)	(160.23)	(135.77)
Employee benefit expenses	163.63	135.65	140.63	442.49	400.79	514.62
Finance costs	22.78	19.03	26.26	65.09	70.45	97.02
Depreciation and amortisation expenses	74.26	65.38	58.41	200.27	176.09	241.89
Other expenses	357.19	316.00	272.32	954.32	731.36	930.49
Total Expenses	3,280.22	3,001.59	2,660.80	8,974.76	7,951.46	10,755.47
III Profit before exceptional items and tax [I-II]	412.62	369.11	348.01	1,108.45	993.89	1,341.34
IV Exceptional items	-	-	-	-	-	-
V Profit before tax [III-IV]	412.62	369.11	348.01	1,108.45	993.89	1,341.34
VI Tax Expense						
Current tax charge	114.74	98.36	103.19	298.35	277.52	361.59
Deferred tax charge/(credit)	(8.43)	(3.44)	(10.60)	(13.68)	(18.40)	(16.70)
Total Tax Expense	106.31	94.92	92.59	284.67	259.12	344.89
VII Profit after tax [V-VI]	306.31	274.19	255.42	823.78	734.77	996.45
VIII Other comprehensive income / (loss)						
A Items that will not be reclassified to profit or loss						
i Remeasurements of the defined benefit plans	(0.04)	(0.04)	1.23	(0.12)	3.71	(0.16)
ii Income tax relating to items that will not be reclassified to profit or loss	0.01	0.01	(0.31)	0.03	(0.93)	0.04
B items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-
Total other comprehensive income/(loss)	(0.03)	(0.03)	0.92	(0.09)	2.78	(0.12)
IX Total comprehensive income (VII + VIII)	306.28	274.16	256.34	823.69	737.55	996.33
Paid up equity share capital (Face value of Rs 2 per share)	110.71	110.58	110.47	110.71	110.47	110.49
Other equity						9,492.91
X Earnings per equity share (in Rs.)						
Basic	5.53*	4.96*	4.62*	14.90*	13.31*	18.05
Diluted	5.53*	4.95*	4.61*	14.88*	13.28*	18.01

*Not annualized

KS



Notes:

1. The financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 21st January, 2025.
2. The standalone financial results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standard (Ind AS) 34, "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
3. The Company deals in Specialty chemicals and considering that the nature of products and the predominant risk and returns of the products are similar, the Company considers it as one operating segment.
4. During the quarter ended 31st December, 2024, the Company has incorporated a wholly owned subsidiary 'Rossari International Limited Company' in Kingdom of Saudi Arabia w.e.f. 24th December, 2024.
5. During the quarter ended 31st December, 2024, the Company has allotted 67,000 equity shares of Rs. 2.00 each pursuant to exercise of options under the approved Rossari Employee Stock Option Plan - 2019.
6. Previous year / period figures have been regrouped to make them comparable with the current year / period figures, which are not material.

For ROSSARI BIOTECH LIMITED



EDWARD MENEZES
Executive Chairman
DIN:00149205

Place : Mumbai

Date : 21st January, 2025



Walker ChandioK & Co LLP

16th Floor, Tower III,
One International Center,
S B Marg, Prabhadevi (W),
Mumbai - 400013
Maharashtra, India
T +91 22 6626 2600

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Rossari Biotech Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of **Rossari Biotech Limited** ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), its associate and joint venture (refer Annexure 1 for the list of subsidiaries, associate and joint venture included in the Statement) for the quarter ended **31 December 2024** and the consolidated year to date results for the period 01 April 2024 to 31 December 2024, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.



Rossari Biotech Limited

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of the other auditors referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We did not review the interim financial results of four subsidiaries included in the Statement, whose financial results reflect total revenues of ₹ 3,097.89 million and ₹ 9,668.46 million, total net profit after tax of ₹ 45.25 million and ₹ 314.97 million, total comprehensive income of ₹ 46.21 million and ₹ 316.04 million, for the quarter and nine-months period ended on 31 December 2024, respectively, as considered in the Statement. The Statement also includes the Group's share of net profit after tax of ₹ 3.06 million and ₹ 6.38 million and total comprehensive income of ₹ 3.08 million and ₹ 6.43 million, for the quarter and nine-months period ended on 31 December 2024, respectively, as considered in the Statement, in respect of an associate, whose interim financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose review reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and associate is based solely on the review reports of such other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors.

6. The Statement includes the interim financial information of four subsidiaries, which have not been reviewed by their auditors, whose interim financial information reflects total revenues of ₹ Nil and ₹ Nil, net loss after tax of ₹ 5.35 million and ₹ 5.35 million, total comprehensive income of (₹ 5.35) million and (₹ 5.35) million for the quarter and nine-months period ended 31 December 2024 respectively, as considered in the Statement. The Statement also includes the Group's share of net profit after tax of ₹ 0.24 million and ₹ 1.89 million, and total comprehensive income of ₹ 0.24 million and ₹ 1.89 million for the quarter and nine-months period ended on 31 December 2024 respectively, in respect of a joint venture, based on their interim financial information, which have not been reviewed by its auditor, and have been furnished to us by the Holding Company's management. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and joint venture, are based solely on such unreviewed interim financial information. According to the information and explanations given to us by the management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of this matter with respect to our reliance on the financial information certified by the Board of Directors.

For Walker Chandiook & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013



Bharat Shetty

Partner

Membership No. 106815



UDIN: 25106815BMJIDZ1149

Place: Mumbai

Date: 21 January 2025

Rossari Biotech Limited
Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Annexure 1

List of entities included in the Statement

Sr. No. Particulars

Subsidiaries	
1	Buzil Rossari Private Limited
2	Rossari Consumer Products Private Limited (Formerly known as Rossari Personal Care Products Private Limited)
3	Unitop Chemicals Private Limited
4	Tristar Intermediates Private Limited
5	Rossari Bangladesh Limited
6	Rossari Global DMCC (Incorporated on 31 May 2024)
7	Rossari International Company Limited (Incorporated on 24 December 2024)
Step down subsidiaries	
1	Rossari Biotech Trading FZE (Incorporated on 07 October 2024)
2	Unistar Thai Co. Ltd (Acquired on 10 December 2024)
Joint Venture	
1	Hextar Unitop SDN BHD (Joint venture of Unitop Chemicals Private Limited)
Associate	
1	Romakk Chemicals Private Limited



ROSSARI BIOTECH LIMITED
(AN ISO9001:2005 & 14001:2015 Certified Company)



Regd. Office : 201 A & B, 2nd Floor, Akruti Corporate Park, L.B.S. Marg, Next to GE Gardens, Kanjurmarg (W) Mumbai – 400078
T +91-22-6123 3800 F +91-22- 25796982 E info@rossari.com W www.rossari.com CIN: L24100MH2009PLC194818

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2024

Rs. in million

Particulars	Quarter ended			Nine months ended		Year Ended
	31st December, 2024	30th September, 2024	31st December, 2023	31st December, 2024	31st December, 2023	31st March, 2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I INCOME						
Revenue from operations	5,127.31	4,983.51	4,637.69	15,007.32	13,578.43	18,305.58
Other Income	5.51	7.19	35.02	22.18	70.56	74.46
Total Income	5,132.82	4,990.70	4,672.71	15,029.50	13,648.99	18,380.04
II EXPENSES						
Cost of materials consumed	3,214.75	3,243.63	2,909.95	9,298.73	9,259.76	12,299.16
Purchase of stock-in-trade	459.94	423.37	253.04	1,308.84	884.58	1,271.28
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(174.22)	(260.00)	66.80	(291.08)	(591.80)	(635.19)
Employee benefits expense	356.94	325.63	260.40	968.41	780.88	1,031.31
Finance costs	49.44	36.81	43.23	123.09	156.68	193.72
Depreciation and amortisation expenses	183.20	151.62	150.88	488.54	443.16	603.90
Other expenses	622.28	591.44	510.80	1,766.51	1,395.18	1,841.46
Total Expenses	4,712.33	4,512.50	4,195.10	13,663.04	12,328.44	16,605.64
III Profit before Share of profit of joint venture, associate, exceptional items and tax [I-II]	420.49	478.20	477.61	1,366.46	1,320.55	1,774.40
IV Share of profit/(loss) of joint venture and associate	3.32	2.90	0.20	8.33	(0.09)	1.75
V Profit before exceptional items and tax [III+IV]	423.81	481.10	477.81	1,374.79	1,320.46	1,776.15
VI Exceptional items	-	-	-	-	-	-
VII Profit before tax [V-VI]	423.81	481.10	477.81	1,374.79	1,320.46	1,776.15
VIII Tax Expense						
Current tax charge	144.24	149.70	159.26	446.52	430.44	557.85
Deferred tax (credit)	(37.45)	(21.93)	(25.35)	(91.07)	(75.55)	(88.59)
Total Tax Expense	106.79	127.77	133.91	355.45	354.89	469.26
IX Profit after tax [VII-VIII]	317.02	353.33	343.90	1,019.34	965.57	1,306.89
X Other comprehensive income / (loss)						
A Items that will not be reclassified to profit or loss						
i Remeasurements of the defined benefit plans	1.24	0.04	1.12	1.31	3.38	0.14
ii Income tax relating to items that will not be reclassified to profit or loss	(0.31)	(0.01)	(0.27)	(0.33)	(0.85)	(0.05)
B Items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-
Total other comprehensive income/(loss)	0.93	0.03	0.85	0.98	2.53	0.09
XI Total comprehensive income (IX + X)	317.95	353.36	344.75	1,020.32	968.10	1,306.98
Profit for the period/year attributable to						
Owners of the Company	317.02	353.33	343.90	1,019.34	965.57	1,306.89
Non Controlling Interest	-	-	-	-	-	-
	317.02	353.33	343.90	1,019.34	965.57	1,306.89
Other Comprehensive Income/(Loss) attributable to						
Owners of the Company	0.93	0.03	0.85	0.98	2.53	0.09
Non Controlling Interest	-	-	-	-	-	-
	0.93	0.03	0.85	0.98	2.53	0.09
Total Comprehensive Income attributable to						
Owners of the Company	317.95	353.36	344.75	1,020.32	968.10	1,306.98
Non Controlling Interest	-	-	-	-	-	-
	317.95	353.36	344.75	1,020.32	968.10	1,306.98
Paid up equity share capital (Face value of Rs 2.00 per share)	110.71	110.58	110.47	110.71	110.47	110.49
Other equity	-	-	-	-	-	10,366.79
Earnings per equity share (in Rs.)						
Basic	5.73*	6.39*	6.23*	18.44*	17.49*	23.67
Diluted	5.72*	6.38*	6.21*	18.41*	17.45*	23.62

*Not annualized



Notes:

1. The financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 21st January, 2025.
2. The consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standard (Ind AS) 34, "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
3. The consolidated financial results include the financial results of three foreign subsidiaries - Rossari Global DMCC, Rossari Bangladesh Limited, Rossari International Limited Company (incorporated on 24th December, 2024), two step-down foreign subsidiaries - Rossari Biotech Trading FZE (incorporated on 7th October, 2024) and Unistar Thai Co. Ltd. (w.e.f. 10th December, 2024, 100% subsidiary of Rossari Global DMCC), four Indian subsidiaries - Unitop Chemicals Private Limited, Tristar Intermediates Private Limited, Buzil Rossari Private Limited and Rossari Consumer Products Private Limited, an associate company - Romakk Chemicals Private Limited and a joint venture company - Hextar Unitop SDN. BHD. - (a joint venture company of Unitop Chemicals Private Limited).
4. The Group deals in Specialty chemicals and considering that the nature of products and the predominant risk and returns of the products are similar, the Group considers it as one operating segment.
5. During the quarter ended 31st December, 2024, the Parent Company has allotted 67,000 equity shares of Rs. 2.00 each pursuant to exercise of options under the approved Rossari Employee Stock Option Plan - 2019.
6. Previous year / period figures have been regrouped to make them comparable with the current year / period figures, which are not material.

For **ROSSARI BIOTECH LIMITED**



EDWARD MENEZES
Executive Chairman
DIN:00149205

Place : Mumbai

Date : 21st January, 2025

